IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Buys 10,000 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 10,000 shares of the firm’s stock in a transaction on Thursday, October 16th. The shares were bought at an average cost of $1.05 per share, with a total value of $10,500.00. Following the transaction, the insider directly owned 735,561 shares of the company’s stock, valued at approximately $772,339.05. This trade represents a 1.38% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

IRIDEX Stock Up 2.2%

NASDAQ:IRIX opened at $0.90 on Friday. The company’s 50 day moving average is $0.73 and its 200-day moving average is $0.95. IRIDEX Corporation has a 12 month low of $0.61 and a 12 month high of $1.65. The firm has a market cap of $15.78 million, a price-to-earnings ratio of -4.49 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last posted its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million for the quarter, compared to analyst estimates of $13.59 million. Research analysts predict that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.00.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Institutional Trading of IRIDEX

Hedge funds have recently modified their holdings of the company. Weber Capital Management LLC ADV bought a new stake in shares of IRIDEX during the second quarter valued at approximately $206,616. United Capital Financial Advisors LLC bought a new position in IRIDEX in the second quarter worth $41,000. Diversify Advisory Services LLC acquired a new stake in IRIDEX during the second quarter worth $30,000. Diversify Wealth Management LLC acquired a new stake in IRIDEX during the first quarter worth $35,000. Finally, Bank of New York Mellon Corp bought a new stake in IRIDEX in the 2nd quarter valued at $29,000. Institutional investors own 20.10% of the company’s stock.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.